Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NextClick settles false-marketing charges

This article was originally published in The Tan Sheet

Executive Summary

NextClick Media, Kenneth Chan and Albert Chen will pay $315,000 to resolve allegations they sold "bogus smoking cessation patches" and illegally debited consumers' bank accounts, the Federal Trade Commission announces Nov. 9. The defendants allegedly failed to tell consumers they would automatically charge them up to $99.95 monthly for products unless they cancelled if they accepted a "free" 10-day trial of various herbal products, including smoking cessation patches Nicocure, Stop Smoking 180 and Zero Nicotine (1"The Tan Sheet" May 12, 2008). The settlement is the latest in an FTC crackdown on negative-option marketing (2"The Tan Sheet" Feb. 16, 2009)

You may also be interested in...

FTC Nails Supplement Marketers For “Bogus” Free Weight-Loss Samples

Firms marketing products or services online must clearly and conspicuously disclose billing practices and obtain affirmative consent before charging consumers, or potentially face hefty fines for violating consumer protection laws, the Federal Trade Commission cautions

FTC sues NextClick Media

The Federal Trade Commission is suing NextClick Media for allegedly deceptive practices involving "free trials" of smoking cessation products, FTC announces May 7. According to the commission, trials for Nicocure were not free, the firm's patches did not work as claimed and the operation was illegally debiting consumers' bank accounts, including making charges without authorization. NextClick Media has agreed to abide by an order in U.S. District Court for the Northern District of California barring the firm from making deceptive claims, restricting its ability to dissipate assets, requiring it to preserve records and other evidence, and accounting for the money the firm made from its venture, FTC says. A trial date has not been set...

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts